Zheng Qi Tibetan Medicine: This stock is a pure Cordyceps concept stock and a leading stock. 20 1 1 In the first half of the year, the company achieved a revenue of 3170,000 yuan, a year-on-year increase of 38.4%; Realized an operating profit of 97.42 million yuan, a year-on-year increase of19.3%; The net profit was 83.33 million yuan, and the earnings per share was 0.2 1 yuan, a year-on-year increase of 1.5%. The operating cash flow per share is 0. 12 yuan. Chinese herbal medicine business is the main source of the company's income growth. In terms of business, in the first half of 20 1 1, the company's leading product, Zheng Qi Xiaotong Plaster, achieved revenue of194 million yuan, a year-on-year increase of1.2%; Ointment revenue exceeded 20 million yuan, up 70% year-on-year, mainly because the company rebuilt the sales channel of ointment product Baimai Ointment during the reporting period, and the sales of this product increased by 5896.9% year-on-year. The company's revenue in the first half of the year increased by 88.28 million yuan, up 38.4% year-on-year (up 58.8% year-on-year in the second quarter), of which Chinese herbal medicines contributed 79 million yuan, up 465% year-on-year. The business income and gross profit of Chinese herbal medicines increased from 7.4% and 65,438+0.4% in the same period last year to 30.3% and 4.2% respectively.
Taiji Group: Asset Disposal and Group Integration Push Up Stock Price
The income of the leading products Huoxiang Zhengqi Liquid and Tailuo Oral Liquid increased by more than 20%. In terms of business, the revenue of 201/kloc-0 in the first half of the year was 2.354 billion yuan, a year-on-year increase of 13. 19%. With the further expansion of the Scout Hall and the advantages of leading commercial enterprises, the income is expected to continue to increase by more than 10%. In terms of gross profit margin, the gross profit margin of the whole industry sector decreased year-on-year 14.2 1% because the upstream Chinese herbal medicines continued to maintain a high level, and western medicines were invited for bidding at low prices, resulting in rising costs. Although the gross profit margin of the commercial sector increased by 0.86% year-on-year due to the expansion of commercial scale and the selection of high-margin varieties, the overall gross profit margin decreased by 2.59% year-on-year. Cordyceps concept stocks are one of them, mainly involving the processing of Cordyceps.